Cardiovascular Protective Effects and Clinical Applications of Resveratrol
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Resveratrol is a naturally occurring phenol that is generated by plant species following injury or attack by bacterial and fungal pathogens. This compound was first described as the French Paradox in 1992. Later in 2003, resveratrol was reported to activate sirtuins in yeast cells. Recent experimental studies have found that resveratrol offers a variety of benefits that include both anticarcinogenic and anti-inflammatory effects in addition to the ability to reverse obesity, attenuate hyperglycemia and hyperinsulinemia, protect heart and endothelial function, and increase the life span. Multiple molecular targets are associated with the cardioprotective capabilities of resveratrol, and therefore, resveratrol has potential for a wide range of new therapeutic strategies for atherosclerosis, ischemia/reperfusion, metabolic syndrome, cardiac failure, and inflammatory alterations during aging. Expectations for application in human patients, however, suffer from a lack of sufficient clinical evidence in support of these beneficial effects. This article reviews recently reported basic research results that describe the beneficial effects of resveratrol in an attempt to condense the evidence observed in clinical trials and provide support for the future development of novel clinical therapeutics in patients with cardiovascular diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
A comprehensive review on metabolic syndrome
Kaur, J. (2014) · Cardiology Research and Practice · doi:10.1155/2014/943162 · Cited by 1,889 · cited 1×
“Metabolic syndrome is a chronic disorder associated with CVD and diabetes risk.(85) This syndrome is categorized by the presence of at least three of the following medical FIG.”
RetractedSmall molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., et al. (2003) · Nature · doi:10.1038/nature01960 · Cited by 3,796 · cited 1×
“The fact that resveratrol mimics calorie restriction in yeast via Sirt2 stimulation, increased DNA stability, and life span extension strongly suggests that this agent may have much more profound effects on human health.(124) This is supported by the potential effects of resveratrol on the main CVDs observed in clinic…”
Role of Endothelial Dysfunction in Atherosclerosis
Davignon, J., & Ganz, P. (2004) · Circulation · doi:10.1161/01.cir.0000131515.03336.f8 · Cited by 2,513
Mechanisms of plaque formation and rupture
Bentzon, J. F., Otsuka, F., Virmani, R., & Falk, E. (2014) · Circulation Research · doi:10.1161/circresaha.114.302721 · Cited by 2,391 · cited 2×
“In type 2 diabetes patients, a daily resveratrol dose of 250–1000 mg caused a significant reduction in LDLcholesterol.(101,102) Also, resveratrol treatments of 150 and 500 mg/day reduced the plasma triglyceride levels in healthy obese men and healthy adult smokers, respectively.”
Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H., van de Weijer, T., Goossens, G. H., Hoeks, J., van der Krieken, S., Ryu, D., Kersten, S., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.10.002 · Cited by 1,320
Pre-Diabetes, Metabolic Syndrome, and Cardiovascular Risk
Grundy, S. M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.080 · Cited by 627
Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus
Bhatt, J. K., Thomas, S., & Nanjan, M. J. (2012) · Nutrition Research · doi:10.1016/j.nutres.2012.06.003 · Cited by 475 · cited 4×
“In type 2 diabetic patients, resveratrol supplement (250 mg/day for 3 months) improved hemoglobin A1c, total cholesterol, and total protein.(102) Thus, oral supplementation of resveratrol was found to be effective for improving glycemic control of diabetes.”
InfluentialHigh-Dose Resveratrol Supplementation in Obese Men
Poulsen, M. M., Vestergaard, P. F., Clasen, B. F., Radko, Y., Christensen, L. P., Stødkilde-Jørgensen, H., Møller, N., Jessen, N., Pedersen, S. B., & Jørgensen, J. O. L. (2013) · Diabetes · doi:10.2337/db12-0975 · Cited by 455
Resveratrol: French Paradox Revisited
Catalgol, B., Batirel, S., Taga, Y., & Ozer, N. K. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00141 · Cited by 449 · cited 3×
“One of the most plausible explanations for this paradox is that French people consume considerably greater quantities of red wine than people in other countries.(3) Red wine contains many polyphenolic compounds, including resveratrol, in addition to alcohol; and this natural phenol has been found to exert healthful ef…”
Kennedy, D. O., Wightman, E. L., Reay, J. L., Lietz, G., Okello, E. J., Wilde, A., & Haskell, C. F. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28641 · Cited by 415 · cited 1×
“117 In recent reviews, 105,118 the cardiovascular effects of re-sveratrol in humans and the challenges that face translating the basic research into therapeutic were also discussed.”
Cited by
The therapeutic potential of resveratrol: a review of clinical trials
Berman, A. Y., Motechin, R. A., Wiesenfeld, M. Y., & Holz, M. K. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0038-6 · Cited by 888
Resveratrol (RV): A pharmacological review and call for further research
Zhang, L.-X., Li, C.-X., Kakar, M. U., Khan, M. S., Wu, P.-F., Amir, R. M., Dai, D.-F., Naveed, M., Li, Q.-Y., Saeed, M., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112164 · Cited by 546
Mitochondria and Reactive Oxygen Species in Aging and Age-Related Diseases
(2018) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2018.05.006 · Cited by 455
Resveratrol and Its Effects on the Vascular System
Breuss, J. M., Atanasov, A. G., & Uhrin, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071523 · Cited by 328
The road ahead for health and lifespan interventions
Gonzalez-Freire, M., Diaz-Ruiz, A., Hauser, D., Martinez-Romero, J., Ferrucci, L., Bernier, M., & de Cabo, R. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101037 · Cited by 118
Effects of Resveratrol on the Renin-Angiotensin System in the Aging Kidney
Jang, I.-A., Kim, E. N., Lim, J. H., Kim, M. Y., Ban, T. H., Yoon, H. E., Park, C. W., Chang, Y. S., & Choi, B. S. (2018) · Nutrients · doi:10.3390/nu10111741 · Cited by 110
“It acts as an activator of silent information regulator 1 (SIRT1) [15,16], exerting anti-senescent effects, as well as antioxidant and anti-inflammatory activities [17,18].”
BackgroundThe synergistic antifungal activity of resveratrol with azoles against Candida albicans
Wang, J., Zhang, X., Gao, L., Wang, L., Song, F., Zhang, L., & Wan, Y. (2021) · Letters in Applied Microbiology · doi:10.1111/lam.13458 · Cited by 29
Resveratrol and Spirulina: Nutraceuticals that potentially improving cardiovascular disease
Wang, Y., Ocampo, M. F., Rodriguez, B., & Chen, J. (2020) · Journal of Cardiovascular Medicine and Cardiology · doi:10.17352/2455-2976.000129 · Cited by 8
Metadata
- Authors
- Cho, S., Namkoong, K., Shin, M., Park, J., Yang, E., Ihm, J., Thu, V. T., Kim, H. K., & Han, J.
- Venue
- Journal of Medicinal Food
- Publisher
- SAGE Publications
- Published
- 2017-04
- Volume
- 20
- Issue
- 4
- Pages
- 323-334
- ISSN
- 1096-620X (ISSN-L)
- 1557-7600
- OpenAlex
- W2598370895
- Cited by
- 96
- References
- 16
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.